VolitionRx Limited (VNRX)
- Previous Close
0.4706 - Open
0.4990 - Bid 0.4549 x 1400
- Ask 0.4890 x 3100
- Day's Range
0.4501 - 0.5000 - 52 Week Range
0.4200 - 0.9000 - Volume
415,648 - Avg. Volume
193,263 - Market Cap (intraday)
45.712M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3100 - Earnings Date May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.92
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
www.volition.comRecent News: VNRX
View More
Performance Overview: VNRX
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VNRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VNRX
View MoreValuation Measures
Market Cap
47.42M
Enterprise Value
49.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
33.01
Price/Book (mrq)
--
Enterprise Value/Revenue
40.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-90.44%
Return on Equity (ttm)
--
Revenue (ttm)
1.23M
Net Income Avi to Common (ttm)
-26.97M
Diluted EPS (ttm)
-0.3100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.26M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.56M